Vyvanse (lisdexamfetamine dimesylate) is a Schedule II CNS stimulant made by Takeda Pharmaceutical. It is FDA-approved for ADHD in adults and children age 6 and older, and for moderate-to-severe binge eating disorder in adults. The brand launched in 2007. On August 25, 2023, the FDA approved 15 manufacturers to produce generic lisdexamfetamine, ending Takeda's exclusivity period.
The cost gap between brand and generic is large. Brand Vyvanse lists at $400 to $558 per month depending on dose. Generic lisdexamfetamine, the same active prodrug, runs $60 to $85 per month at CVS or Walgreens with a GoodRx coupon. For anyone paying out of pocket, switching to generic is the single most effective cost reduction. The deductible and out-of-pocket maximum on your plan will determine how much of that cost you bear before coverage kicks in. The active ingredient is identical: lisdexamfetamine dimesylate converts to d-amphetamine in the body, and FDA-approved generics must demonstrate bioequivalence to the brand.
One ongoing complication: generic lisdexamfetamine has faced intermittent supply gaps since 2023 because DEA aggregate production quota limits for amphetamine-class Schedule II drugs constrain how much active ingredient manufacturers can produce each year. The DEA raised production quotas in 2024 and again in 2025, and availability has improved broadly, but localized pharmacy-level stock-outs on specific generic manufacturers still occur. Call your pharmacy before relying on a generic fill. Patients who qualify for Medicaid generally pay $1 to $4 per prescription and face fewer access barriers than those relying on commercial insurance prior authorization.
What Vyvanse Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same vyvanse can cost many times more at a hospital than at your local pharmacy:
2026 Vyvanse Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Retail pharmacy (brand Vyvanse, no insurance) | $400 - $558/month | Cash price at pharmacy counter, dose-dependent (20 mg to 70 mg) |
| Retail pharmacy (generic lisdexamfetamine, GoodRx coupon) | $60 - $85/month | Available at CVS and Walgreens with free GoodRx coupon; subject to pharmacy stock |
| Commercially insured (Takeda savings card) | As low as $30/month on brand Vyvanse | Commercially insured only; not valid with Medicare, Medicaid, or other federal programs |
| Medicare Part D | Varies by plan tier; $2,100 annual OOP cap (2026) | Covered for ADHD indication only, not binge eating disorder; prior auth common |
| Medicaid | $1 - $4/prescription | Most states cover lisdexamfetamine; prior authorization may apply |
Retail prices reflect 2026 cash prices. GoodRx coupon pricing varies by pharmacy location and dose. Part D cost-sharing depends on plan formulary tier. Walmart's $4 generic program does not apply to Schedule II controlled substances.
Source: GoodRx 2026, CMS Medicare Part D 2026, Takeda Pharmaceuticals
Why Hospitals Charge So Much
Vyvanse is almost always dispensed at the retail pharmacy and billed through Part D or commercial insurance. It is not a drug typically administered in a hospital setting. However, if a patient is admitted for a psychiatric stay or another medical event and is already prescribed Vyvanse, the hospital may dispense it from their formulary during the inpatient stay. In that case, the drug gets billed at the hospital's chargemaster rate, which is set internally and not based on retail pharmacy pricing or any government reference price.
Because lisdexamfetamine is a Schedule II controlled substance, hospital dispensing requires additional documentation, logging, and chain-of-custody compliance. These administrative costs are sometimes used to justify higher per-unit billing. A drug retailing for $15 to $20 per capsule at the pharmacy can appear on a hospital bill at $50 to $150 or more per capsule when administered inpatient.
If you see Vyvanse or lisdexamfetamine on an inpatient bill, compare the per-unit price to the 2026 GoodRx retail rate for that dose. Any charge more than 3x to 5x the retail rate is a reasonable target for a billing dispute or itemized bill review request.
Patient Assistance Programs
Takeda discontinued the Help at Hand free-drug program for Vyvanse effective October 2023, with final coverage ending December 31, 2023. That program no longer exists for Vyvanse. The main cost-reduction options available in 2026 are the Takeda commercial savings card for insured patients, GoodRx discount coupons for generic lisdexamfetamine, and NeedyMeds as a directory for any independent assistance programs.
Patient assistance programs for Vyvanse| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Takeda Vyvanse Savings Card (commercially insured only) | As low as $30/month for brand Vyvanse; up to $60 off per fill; not valid for Medicare, Medicaid, or federal program beneficiaries | vyvanse.com |
| GoodRx / SingleCare (generic lisdexamfetamine) | $60 - $85/month for generic lisdexamfetamine at CVS and Walgreens; no income requirement; open to anyone regardless of insurance status | goodrx.com |
| NeedyMeds Drug Assistance Database | Directory of all current manufacturer and independent assistance programs for lisdexamfetamine; check for any newly announced programs | needymeds.org |
The Takeda Help at Hand PAP was discontinued for Vyvanse in October 2023. As of 2026, there is no income-based free-drug program for brand Vyvanse. Uninsured patients should use generic lisdexamfetamine with a GoodRx coupon as the most accessible low-cost option. Takeda's savings card is for commercially insured patients only and cannot be combined with federal insurance programs.
Source: Takeda Help at Hand (helpathandpap.com, verified May 2026), NeedyMeds.org, GoodRx 2026
Medicare Part D
Medicare Part D covers lisdexamfetamine (brand Vyvanse or generic) when prescribed for ADHD. Medicare specifically excludes coverage when Vyvanse is prescribed for binge eating disorder or weight management, because drugs prescribed primarily for weight control are excluded from Part D by statute. If your prescription is written for binge eating disorder and you are on Medicare, it will not be covered under Part D.
Lisdexamfetamine is typically placed on a non-preferred tier in Part D formularies, which means higher cost-sharing than preferred generics. Prior authorization is common: plans often require documentation of a confirmed ADHD diagnosis and may require a trial of another stimulant first. As of 2026, once you meet your plan's cost-sharing obligations across the year, the $2,100 annual Part D out-of-pocket cap applies. After hitting the cap, your plan covers covered drugs at no additional cost for the rest of the year.
There is no special monthly cap on Vyvanse under Medicare the way there is for insulin ($35 per month). The $2,100 annual OOP cap is the applicable protection. The Takeda commercial savings card cannot be used by Medicare beneficiaries. This is a federal anti-kickback compliance requirement, not a manufacturer policy choice.
Common Vyvanse Billing Errors
Vyvanse and lisdexamfetamine generate specific billing errors at both the pharmacy and hospital level. The Schedule II status adds documentation requirements that can produce errors:
- Brand Vyvanse billed instead of generic lisdexamfetamine, or vice versa, resulting in wrong formulary tier cost-sharing
- Prescription filled for wrong dose (for example, 70 mg billed when 50 mg was prescribed), which inflates both unit cost and copay
- Medicare patient billed under binge eating disorder diagnosis code rather than ADHD code. Medicare only covers the ADHD indication, so the diagnosis code on the claim determines whether the claim is paid
- Inpatient hospital billed for Vyvanse at chargemaster rate when the patient's own supply (brought from home) was actually used
- GoodRx coupon not applied at time of fill. Schedule II prescriptions cannot be transferred between pharmacies, so you must present the coupon at the dispensing pharmacy at time of fill. You cannot move a Schedule II prescription to a cheaper pharmacy mid-month
- 30-day supply billed as a 90-day supply (most Part D plans and state Medicaid programs reject 90-day fills for Schedule II drugs) causing a quantity mismatch denial
Frequently Asked Questions
How much does Vyvanse cost without insurance in 2026?
Brand Vyvanse costs $400 to $558 per month at the pharmacy counter without insurance in 2026, depending on dose. Generic lisdexamfetamine (same active ingredient, FDA-approved since August 2023) costs $60 to $85 per month with a GoodRx coupon at CVS or Walgreens. For anyone paying cash, switching to generic is the single most effective cost reduction available.
Is generic Vyvanse (lisdexamfetamine) as effective as brand Vyvanse?
Yes. The FDA requires generic drugs to demonstrate bioequivalence to the brand. Generic lisdexamfetamine dimesylate contains the same active ingredient at the same dose and converts to d-amphetamine in the body identically to brand Vyvanse. The FDA approved 15 generic manufacturers starting August 25, 2023, after Takeda's exclusivity expired. Most clinical guidance supports substitution.
Does Medicare cover Vyvanse?
Medicare Part D covers lisdexamfetamine (brand or generic) when prescribed for ADHD. It does not cover Vyvanse prescribed for binge eating disorder. Medicare excludes drugs primarily for weight control by statute. Prior authorization is common, and lisdexamfetamine is typically on a non-preferred tier. The 2026 Part D annual out-of-pocket cap is $2,100.
Can I use a GoodRx coupon for Vyvanse or generic lisdexamfetamine?
Yes for generic lisdexamfetamine, which costs $60 to $85 per month with GoodRx at CVS or Walgreens. Because lisdexamfetamine is a Schedule II controlled substance, the prescription cannot be transferred between pharmacies. You must present the GoodRx coupon at the specific pharmacy where you fill the prescription, at the time of fill. Compare prices before your first fill and note that Walmart and Costco do not participate in GoodRx programs for Schedule II drugs.
Does Takeda still have a free Vyvanse program for uninsured patients?
No. Takeda discontinued the Help at Hand patient assistance program for Vyvanse in October 2023. Final coverage for previously enrolled patients ended December 31, 2023. As of 2026, Takeda's Help at Hand program does not list Vyvanse among its covered products. Uninsured patients should use generic lisdexamfetamine with a GoodRx coupon ($60 to $85 per month at CVS or Walgreens), which is open to anyone regardless of insurance status.
What is the Takeda Vyvanse savings card and who qualifies?
The Takeda savings card reduces brand Vyvanse to as little as $30 per month for eligible commercially insured patients, covering up to $60 off per fill. Eligibility requires active commercial (private) insurance. The card is not valid for patients on Medicare, Medicaid, TRICARE, or any other government-funded health program. Enroll at vyvanse.com or through your prescriber's office.
Is Vyvanse still in shortage in 2026?
Brand Vyvanse from Takeda is generally available and not listed as in shortage by the FDA as of 2026. Generic lisdexamfetamine continues to face localized pharmacy-level stock-outs from specific manufacturers, driven by DEA production quota constraints on Schedule II amphetamine-class drugs. The DEA increased production quotas in 2024 and again in 2025. If your pharmacy is out of generic, call others nearby or ask your prescriber whether brand (with the savings card) is an option.
Can Medicaid patients get Vyvanse or generic lisdexamfetamine?
Most state Medicaid programs cover lisdexamfetamine for ADHD with minimal copays of $1 to $4 per prescription. Prior authorization is common: states typically require confirmation of an ADHD diagnosis and may require documentation that other ADHD treatments have been tried first. Contact your state Medicaid office or your prescriber to initiate prior authorization if needed.
